Equity
Additional Paid-In Capital
Bristol-Myers Squibb Additional Paid-In Capital decreased by 0.0% to $46.37B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.8%, from $46.01B to $46.37B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows relatively stable performance with a 0.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase typically signals successful equity financing or the accounting impact of employee stock option exercises.
Detailed definition
Additional paid-in capital represents the amount of capital received from shareholders in excess of the par value of the...
Peer comparison
High levels are common in R&D-intensive industries like pharma, where equity issuance is often used to fund long-term drug development pipelines.
Metric ID:
additional_paid_in_capitalHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $44.06B | $44.29B | $44.36B | $43.76B | $44.38B | $44.96B | $45.17B | $45.14B | $45.30B | $44.85B | $45.68B | $45.66B | $45.77B | $45.90B | $46.02B | $46.01B | $46.13B | $46.27B | $46.39B | $46.37B |
| QoQ Change | — | +0.5% | +0.2% | -1.4% | +1.4% | +1.3% | +0.5% | -0.1% | +0.4% | -1.0% | +1.9% | -0.1% | +0.2% | +0.3% | +0.3% | -0.0% | +0.3% | +0.3% | +0.3% | -0.0% |
| YoY Change | — | — | — | — | +0.7% | +1.5% | +1.8% | +3.2% | +2.1% | -0.2% | +1.1% | +1.1% | +1.0% | +2.3% | +0.7% | +0.8% | +0.8% | +0.8% | +0.8% | +0.8% |
Range$43.76B – $46.39B
CAGR+1.1%
Avg YoY Growth+1.2%
Median YoY Growth+0.9%
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's additional paid-in capital?
- Bristol-Myers Squibb (BMY) reported additional paid-in capital of $46.37B in Q1 2026.
- How has Bristol-Myers Squibb's additional paid-in capital changed year-over-year?
- Bristol-Myers Squibb's additional paid-in capital increased by 0.8% year-over-year, from $46.01B to $46.37B.
- What is the long-term trend for Bristol-Myers Squibb's additional paid-in capital?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's additional paid-in capital has grown at a 0.9% compound annual growth rate (CAGR), from $44.33B to $46.39B.
- What does additional paid-in capital mean?
- The surplus capital contributed by investors above the par value of the shares.